MoonLake Immunotherapeutics explores sale | Reuters News Agency

Business & FinanceDealsHealth

MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.

Market Impact

MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday, giving the company a market value of $3.3 billion.

Article Tags

Topics of Interest: Business & FinanceDealsHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Europe

Countries: Switzerland

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

MoonLake Immunotherapeutics explores sale | Reuters News Agency

Business & FinanceDealsHealth

MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.

Market Impact

MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday, giving the company a market value of $3.3 billion.

Article Tags

Topics of Interest: Business & FinanceDealsHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Europe

Countries: Switzerland

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *